Who we are
BRAVE Partners
Located at the University of the Witwatersrand in Johannesburg, South Africa, Wits-ALIVE was established in 2017 and is the African Coordinating Center for BRAVE. Wits-ALIVE actively engages vaccinologists across African countries to create new opportunities, build capacity and expand an African network of vaccinology expertise.
Located in Navrongo, Ghana, the Navrongo Health Research Centre (NHRC) has operated Health and Demographic Surveillance Systems (HDSS) in districts of Northern Ghana for over thirty years. It has been involved in many ground-breaking multi-centre vaccine and drug trials both within the demographic surveillance areas and nationally. NHRC has vast experience in monitoring and evaluation of programmes and surveillance. NHRC is collecting BRAVE data across five healthcare facilities and two HDSS sites.
KEMRI-Wellcome Trust Research Programme (KWTRP) is a leading health research programme based in Kilifi and Nairobi in Kenya and Mbale in Uganda. KWTRP's contribution to the BRAVE project leverages its strong hospital and community surveillance platforms, clinical research capacity, and population health expertise. KWTRP is collecting BRAVE data across one healthcare facility and one HDSS site.
Located in Abuja, the International Foundation Against Infectious Diseases in Nigeria (IFAIN) has a well-established platform in infectious disease projects and graduate student training. The Site Lead at IFAIN is affiliate to the University of Alabama at Birmingham and provides supervisory oversight and leads the coordination of the four Nigerian sites under IFAIN (Owo, Bauchi, Benin and Irrua). IFAIN is collecting BRAVE data from four healthcare facilities across these locations.
Located in Kigali, Rwanda, Eagle Research Centre (ERC) is a research institution experienced in advocacy, managing and conducting research projects, international collaborations and large, multinational clinical trials. ERC is collecting BRAVE data from two healthcare facilities.
Located at the University of Kinshasa in the Democratic Republic of Congo (DRC), the Clinical Pharmacology and Pharmacovigilance Unit (UPC-PV), serves as the National Pharmacovigilance Center of DRC. UPC-PV is collecting BRAVE data across two healthcare facilities and one HDSS site.
The London School of Hygiene & Tropical Medicine (LSHTM) is one of the world’s leading public health universities, renowned for its research and postgraduate education in public and global health. LSHTM provides BRAVE scientific advisory and project management support to the KEMRI Wellcome Trust Research Programme.
The University of Alabama at Birmingham (UAB) is a leading academic medical and research institution in the United States, internationally recognised for its strengths in public health, epidemiology, clinical research, and data science. UAB has extensive experience in large-scale health data analysis and collaborative research addressing vaccine safety, infectious diseases, and population health.
Auckland UniServices Limited is a wholly owned not-for-profit subsidiary of the University of Auckland, New Zealand. UniServices hosts GVDN’s Global Coordinating Centre.
Coordination and Funding
Established in 2019, the Global Vaccine Data Network (GVDN) collaborates with renowned research institutions, policy makers, and vaccine related organisations to establish a harmonised and evidence-based approach to evaluating vaccine safety and effectiveness. GVDN is supported by a Global Coordinating Centre (CGG) based at Auckland UniServices Limited that provides comprehensive support to researchers.
The Coalition for Epidemic Preparedness Innovations (CEPI) was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic disease threats and enable equitable access to them. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens and is also advancing the development of rapid response platforms for vaccines against a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. BRAVE is funded in whole by CEPI.